Study of Samalizumab in Patients With Advanced Cancer | NCT02987504

NCT02987504

Protocol Section

Identification Module

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Status Module

Name	Class
Quintiles, Inc.	INDUSTRY

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Samalizumab 10, 15, 20 milligrams (mg)/kilogram (kg) Dose	Experimental	Participants received escalating doses of 10, 15, and 20 mg/kg of samalizumab IV every 21 days. Enrollment at each dose level and safety assessments were completed prior to enrolling at the next dose level; intra-participant dose escalation was not allowed. 3 participants were enrolled into a dose cohort: If 0/3 participants developed dose limiting toxicities (DLT) within Cycle 1, enrollment began at the next higher dose to a maximum of 20 mg/kg. If 1/3 participants developed a DLT, the dose cohort was expanded to include 3 new participants. If 0/3 new participants developed a DLT within Cycle 1, enrolment began at the next higher dose level. If ≥1 of 3 new participants developed a DLT within Cycle 1, dose-escalation was terminated, and the dose level 5 mg/kg below the current dose was considered the MTD. If ≥2 of 3 participants developed DLTs within Cycle 1, dose-escalation was terminated, and the dose level 5 mg/kg below the current dose was considered the MTD.	Drug: Samalizumab

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Samalizumab	Drug	Samalizumab is a humanized, anti CD200 monoclonal antibody provided as a sterile 5 mg/milliliters (mL) solution for IV administration.	Samalizumab 10, 15, 20 milligrams (mg)/kilogram (kg) Dose

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Number Of Participants Experiencing DLT Graded According To CTCAE Version 4.03, Observed In The Cycle 1 In Order To Meet The Objective Of Assessment Of The MTD	Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]	Safety monitoring began at the informed consent obtained and continued up to 28 days after the last dose of samalizumab or until new anti-tumor therapy, whichever was earlier.
Maximum Plasma Concentration After Administration Of Samalizumab		21 days in Cycle 1
Area Under The Plasma Drug Concentration-time Curve After Administration Of Samalizumab		21 days in Cycle 1

Measure	Description	Time Frame
Objective Response Rate Using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1		Up to 2 Years
Disease Control Rate Using RECIST 1.1		Up to 2 Years

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Male or female participant was ≥ 18 years of age at Screening.
Eastern Cooperative Oncology Group performance status of 0 to 2.
Participant had advanced/metastatic cancer with disease progression after treatment with all available therapies known to confer clinical benefit.
Participant had a life expectancy of greater than 12 weeks.

Exclusion Criteria:

Participant had a symptomatic brain metastasis.
Participant had active gastrointestinal bleeding as evidenced by either hematemesis or melena.
Participant had acute gastrointestinal ulcers.
Participant had a history of any cancer other than the present condition (except nonmelanoma skin cancer or carcinoma in situ of the cervix), unless in complete remission and off all therapy for that disease for a minimum of 3 years.
Participant with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of study drug administration.
Participant had an active infection requiring therapy.
Participant's serum was positive for the presence of hepatitis B surface antigen, antibodies to hepatitis C virus, or antibodies to human immunodeficiency virus 1/2.
Participant had significant cardiovascular impairment (history of New York Heart Association Functional Classification system Class III or IV) or a history of myocardial infarction or unstable angina within the past 6 months prior to study drug treatment.
The participant's most recent test values within 14 days before the date of entry met the following standards:
- Bone marrow function: neutrophil count ≤1500/millimeter (mm)^3, hemoglobin ≤9.0 grams/deciliter, platelet count ≤100,000/mm^3.
- Liver function: total bilirubin ≥1.5 x the upper limit of normal (ULN) based on the standard value of each institution, aspartate aminotransferase and alanine aminotransferase ≥2.5 x ULN based on the reference laboratory.
- Renal function: serum creatinine ≥1.5 x ULN based on the reference laboratory.
Participant had ongoing immune-stimulated adverse events from other immunotherapies (for example, pneumonitis, thyroiditis, or hepatitis) or a history of pneumonitis.
Participant had received chemotherapy, targeted therapy, and/or immunotherapy within the 28 days prior to first dose of study drug, or within a Washout Period for the chemotherapy, targeted therapy, and/or immunotherapy of 5 half-lives, whichever occurred first.
Participant had toxicities from previous immunotherapy that had not resolved to Grade 1.

Facility	Status	City	State	ZIP	Country	Contacts
		New Haven	Connecticut	06510	United States